Company · dendreon-7eb2fd3a
Dendreon
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Dendreon. Companies, record dendreon-7eb2fd3a. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/dendreon-7eb2fd3a
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Dendreon
- Trials
- 31
- As lead sponsor
- 20
- As collaborator
- 11
- Recruiting
- 2
- Active, recruiting or not
- 5
- Completed
- 21
- Stopped early, withdrawn or suspended
- 5
- Posted results
- 21
- Trials by phase
- Phase 1 4, Phase 2 16, Phase 3 5
- Drugs its trials test
- 11
- Comparisons calculated in its trials
- 25
- First trial registered
- 2003-07-24
- Last update
- 2026-09-15
Source ClinicalTrials.gov
Pipeline11
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| SIPULEUCEL-T | Phase 3 | 23 | 16 | 2 | ACP3 | Prostatic acid phosphatase binding agent | https://conductscience.org/library/drugs/CHEMBL1237024 | Open Targets |
| ENZALUTAMIDE | Phase 2 | 2 | 1 | 0 | AR | Androgen Receptor antagonist | https://conductscience.org/library/drugs/CHEMBL1082407 | Open Targets |
| ABIRATERONE | Phase 2 | 1 | 0 | 0 | AR, CYP17A1, SRD5A1, SRD5A2, SRD5A3 | Androgen Receptor antagonist; Cytochrome P450 17A1 inhibitor; Steroid 5-alpha-reductase inhibitor | https://conductscience.org/library/drugs/CHEMBL254328 | Open Targets |
| ABIRATERONE ACETATE | Phase 2 | 1 | 1 | 0 | CYP17A1 | Cytochrome P450 17A1 inhibitor | https://conductscience.org/library/drugs/CHEMBL271227 | Open Targets |
| APALUTAMIDE | Phase 2 | 1 | 0 | 0 | AR | Androgen Receptor antagonist | https://conductscience.org/library/drugs/CHEMBL3183409 | Open Targets |
| IPILIMUMAB | Phase 2 | 1 | 0 | 0 | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor | https://conductscience.org/library/drugs/CHEMBL1789844 | Open Targets |
| LAPULEUCEL-T | Phase 2 | 1 | 1 | 0 | https://conductscience.org/library/drugs/CHEMBL2108615 | Open Targets | ||
| LEUPROLIDE ACETATE | Phase 2 | 1 | 1 | 0 | GNRHR | Gonadotropin-releasing hormone receptor agonist | https://conductscience.org/library/drugs/CHEMBL1200775 | Open Targets |
| RADIUM RA-223 | Phase 2 | 1 | 0 | 0 | https://conductscience.org/library/drugs/CHEMBL4297420 | Open Targets | ||
| TESTOSTERONE CYPIONATE | Phase 2 | 1 | 0 | 1 | AR | Androgen Receptor agonist | https://conductscience.org/library/drugs/CHEMBL1201101 | Open Targets |
1 to 10 of 11
See all 11 pipelineTrials31
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | Collaborator | Phase 1 | Not yet recruiting | Interventional | 30 | 2026-11-30 | https://conductscience.org/library/trials/NCT07756593 | ClinicalTrials.gov | ||
| NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Lead sponsor | Phase 2 | Recruiting | Interventional | 400 | 2023-10-02 | SIPULEUCEL-T | https://conductscience.org/library/trials/NCT06134232 | ClinicalTrials.gov | |
| NCT06100705 | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | Collaborator | Phase 2 | Recruiting | Interventional | 26 | 2023-12-20 | SIPULEUCEL-T, TESTOSTERONE CYPIONATE | https://conductscience.org/library/trials/NCT06100705 | ClinicalTrials.gov | |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer | Collaborator | Phase 1 | Active, not recruiting | Interventional | 15 | 2023-11-12 | SIPULEUCEL-T | https://conductscience.org/library/trials/NCT05806814 | ClinicalTrials.gov | |
| NCT05751941 | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | Collaborator | Phase 2 | Active, not recruiting | Interventional | 26 | 2023-02-14 | ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, SIPULEUCEL-T | https://conductscience.org/library/trials/NCT05751941 | ClinicalTrials.gov | |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer | Lead sponsor | Phase 3 | Completed | Interventional | 532 | 2018-10-18 | 2024-10-08 | SIPULEUCEL-T | https://conductscience.org/library/trials/NCT03686683 | ClinicalTrials.gov |
| NCT03024216 | Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer | Collaborator | Phase 1 | Completed | Interventional | 37 | 2017-02-06 | ATEZOLIZUMAB, SIPULEUCEL-T | https://conductscience.org/library/trials/NCT03024216 | ClinicalTrials.gov | |
| NCT02463799 | Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | Collaborator | Phase 2 | Completed | Interventional | 36 | 2016-02-22 | 2021-07-08 | RADIUM RA-223, SIPULEUCEL-T | https://conductscience.org/library/trials/NCT02463799 | ClinicalTrials.gov |
| NCT02232230 | A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T | Collaborator | Completed | Observational | 20 | 2014-06 | SIPULEUCEL-T | https://conductscience.org/library/trials/NCT02232230 | ClinicalTrials.gov | ||
| NCT02042053 | PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer | Collaborator | Not applicable | Terminated | Interventional | 10 | 2014-01 | https://conductscience.org/library/trials/NCT02042053 | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsConditions27
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Prostate Cancer | 16 |
| Metastatic Prostate Cancer | 3 |
| Castration-Resistant Prostate Cancer | 2 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2 |
| Prostate Cancer Metastatic | 2 |
| Adenocarcinoma of the Prostate | 1 |
| Advanced Prostate Cancer | 1 |
| Cancer of Prostate | 1 |
| Cancer of the Prostate | 1 |
| Castrate Refractory Metastatic Prostate Cancer (mCRPC) | 1 |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 conditionsPartners19
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| University of California, San Francisco | Other | 2 | ClinicalTrials.gov | |
| Bayer | Industry | 1 | https://conductscience.org/library/companies/bayer-107eaa27 | ClinicalTrials.gov |
| Bristol-Myers Squibb | Industry | 1 | https://conductscience.org/library/companies/bristol-myers-squibb-1255780f | ClinicalTrials.gov |
| Genentech, Inc. | Industry | 1 | https://conductscience.org/library/companies/genentech-inc-7f48360d | ClinicalTrials.gov |
| GenesisCare USA | Other | 1 | ClinicalTrials.gov | |
| H. Lee Moffitt Cancer Center and Research Institute | Other | 1 | ClinicalTrials.gov | |
| ImmunityBio, Inc. | Industry | 1 | https://conductscience.org/library/companies/immunitybio-inc-454110c5 | ClinicalTrials.gov |
| M.D. Anderson Cancer Center | Other | 1 | ClinicalTrials.gov | |
| NYU Langone Health | Other | 1 | ClinicalTrials.gov | |
| PRA Health Sciences | Industry | 1 | https://conductscience.org/library/companies/pra-health-sciences-dc488a32 | ClinicalTrials.gov |
1 to 10 of 19
See all 19 partnersData dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/dendreon-7eb2fd3a
GET https://conductscience.org/api/companies/v1/dendreon-7eb2fd3a/trials?page=2